

Serum Albumin Targeted, pH-Dependent Magnetic Resonance Relaxation Agents

Loïck Moriggi,^[a] Mohammad A. Yaseen,^[a] Lothar Helm,^[b] and Peter Caravan^{*[a]}

Abstract: The objective of this work was the synthesis of serum albumin targeted, Gd^{III}-based magnetic resonance imaging (MRI) contrast agents exhibiting a strong pH-dependent relaxivity. Two new complexes (**Gd-glu** and **Gd-bbu**) were synthesized based on the DO3A macrocycle modified with three carboxyalkyl substituents α to the three ring nitrogen atoms, and a biphenylsulfonamide arm. The sulfonamide nitrogen coordinates the Gd in a pH-dependent fashion, resulting in a decrease in the hydration state, q , as pH is increased and a resultant decrease in relaxivity (r_1). In the absence of human serum albumin (HSA), r_1 increases from 2.0 to 6.0 mm²s⁻¹ for **Gd-glu** and from 2.4 to 9.0 mm²s⁻¹ for **Gd-bbu**

from pH 5 to 8.5 at 37°C, 0.47 T, respectively. These complexes (0.2 mM) are bound (>98.9%) to HSA (0.69 mM) over the pH range 5–8.5. Binding to albumin increases the rotational correlation time and results in higher relaxivity. The r_1 increased 120% (pH 5) and 550% (pH 8.5) for **Gd-glu** and 42% (pH 5) and 260% (pH 8.5) for **Gd-bbu**. The increases in r_1 at pH 5 were unexpectedly low for a putative slow tumbling $q=2$ complex. The **Gd-bbu** system was investigated further. At pH 5, it binds in a stepwise

Keywords: gadolinium • imaging • imaging agents • second-sphere relaxation • serum albumin

fashion to HSA with dissociation constants $K_{d1}=0.65$, $K_{d2}=18$, $K_{d3}=1360$ μ M. The relaxivity at each binding site was constant. Luminescence lifetime titration experiments with the Eu^{III} analogue revealed that the inner-sphere water ligands are displaced when the complex binds to HSA resulting in lower than expected r_1 at pH 5. Variable pH and temperature nuclear magnetic relaxation dispersion (NMRD) studies showed that the increased r_1 of the albumin-bound $q=0$ complexes is due to the presence of a nearby water molecule with a long residency time (1–2 ns). The distance between this water molecule and the Gd ion changes with pH resulting in albumin-bound pH-dependent relaxivity.

Introduction

The desire to produce contrast agents that are activated by changes in physiological pH is driven by the fact that the extracellular pH of solid tumors is more acidic than that of healthy tissue.^[1] Tissue ischemia, for example, in ischemic heart disease and stroke, also results in a lower extracellular pH.^[2] Thus, pH can be a valuable biomarker for the identification of tumors and ischemic tissue. There has been great interest in mapping pH change and quantifying pH, in vivo, by using a range of imaging techniques including positron emission tomography (PET), magnetic resonance imaging and spectroscopy (MRI and MRS) and optical imaging.^[1a,3]

MRI has better spatial resolution than MRS or PET, and is not limited by light scattering and absorption like optical imaging. pH-Dependent MRI requires a metal-based contrast agent, proton relaxation enhancing properties (relaxivity) of which change with pH. Water is imaged in MRI and the contrast agent acts as a catalyst to enhance water proton relaxation rates ($1/T_1$, $1/T_2$) with relaxivity defined as the change in relaxation rate normalized to agent concentration. A change in pH can alter relaxivity by changing the hydration state of the inner- or second-coordination sphere,^[4] by affecting prototropic exchange,^[5] or by changing the rotational diffusion rate of the molecule.^[6] For example, lowering pH can result in protonation of a donor atom on a multidentate ligand opening up a site(s) for a water ligand to coordinate the metal ion and increase relaxivity.^[4]

There are several examples of pH-dependent contrast agents. However, quantification of pH by using MRI is challenging because the MR signal change depends on both the relaxivity of the probe (pH-dependent) and its concentration. This challenge has been met through two techniques. One approach is to use two very similar contrast agents, one pH-independent and one pH-dependent. The MR signal intensity versus time curve of the pH-independent contrast agent is used to estimate time-dependent concentration of the contrast agent, and it is assumed that the pH-dependent agent will have the same concentration profile.^[7] The limita-

[a] Dr. L. Moriggi, Dr. M. A. Yaseen, Prof. P. Caravan
A. A. Martinos Center for Biomedical Imaging
Department of Radiology
Massachusetts General Hospital and Harvard Medical School
Charlestown, MA 02129 (USA)
E-mail: caravan@nmr.mgh.harvard.edu


[b] Prof. L. Helm
Institut de Chimie Moléculaire et Biologique
Ecole Polytechnique Fédérale de Lausanne, EPFL-BCH
1015 Lausanne (Switzerland)

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/chem.201103344>.

tion of this approach is the assumption of identical pharmacokinetics of two different compounds. Another approach is to incorporate a marker that is independently quantifiable within the pH-dependent contrast agent. For example, ^{19}F MR spectroscopy has been used to quantify concentration,^[8] but MR spectroscopy is limited to high concentrations and lower spatial and temporal resolution compared to gadolinium enhanced MRI. Incorporation of a PET reporter like ^{18}F can provide quantification,^[9] but this requires the use of a simultaneous MR–PET device.

We reasoned that a contrast agent with a large enough relaxivity change could identify ischemic and acidic tissue. The pH range of physiological interest is between pH 6–7.5. The ideal pH-dependent contrast agent would have a very high relaxivity that is detectable at low concentrations, but more importantly would have a large change in relaxivity, Δr_1 , from pH 6.8 to 7.4. If the percentage change in relaxivity is higher than the difference in concentration between ischemic and normal tissue, then low pH regions could be identified, at least qualitatively. Such a high relaxivity, high delta relaxivity pH agent could also be adapted for quantitative pH imaging by using the approaches described above.

We looked to the literature to identify promising approaches. In ischemic and/or cancerous tissue, low pH is observed in the extracellular interstitial space. A pH-dependent contrast agent should be small enough to rapidly cross the endothelial barrier into the extracellular space. This rules out pH-dependent nanomaterials like liposomes,^[10] carbon nanotubes,^[11] large dendrimers,^[6b,c] and polymers.^[6a,d] Also, preferred would be contrast agents the relaxivity of which increases with decreasing pH, such that pathology would appear bright in an image. One class of compounds that appeared particularly promising was Gd(DO3A) derivatives with a pendant sulfonamide reported by Lowe et al. (Scheme 1, in which $\text{R} = \text{CF}_3$, OMe, or Me).^[4a] At high pH, the sulfonamide nitrogen is deprotonated and coordinates the Gd^{III} resulting in a complex with no inner-sphere water ligands ($q=0$). At low pH, the sulfonamide is protonated and does not coordinate, opening up two sites for water ligation and concomitant higher relaxivity.



Scheme 1. q-Modulated pH-dependent contrast agents.

These compounds had several favorable features. First, relaxivity increased significantly as pH was lowered. Second, the pK_a of the sulfonamide was in the appropriate range for a physiological pH sensor, and this pK_a could be modulated by the choice of electronic substituent on the aromatic ring. Third, the macrocyclic DO3A core should impart high thermodynamic stability and kinetic inertness with respect to Gd decomplexation. Finally, the pendant carboxylate arms overcame a major limitation of other Gd(DO3A) derivatives, that of anion binding and quenching of relaxivity by water displacement.

Here, we report two new ligands that build on the design of Lowe et al.^[4a] The Gd^{III} complexes were prepared and evaluated as pH-dependent contrast agents. The pH-dependent relaxivity, serum albumin binding, and self-association of these complexes was explored. In addition, the Eu^{III} complexes were synthesized to explore the effects of protein binding and anion concentration on hydration number.

Results and Discussion

Compound strategy and synthesis: We sought to build on the successful molecular design of Lowe et al.^[4a] Their sulfonamide derivatives showed an excellent relaxivity dependence on pH brought about by a change in hydration number from $q=0$ to $q=2$ when the sulfonamide nitrogen was protonated. Importantly, the pendant carboxylate arms appeared to prevent anion coordination to the lanthanide when $q=2$.^[12] Anion coordination would have the effect of displacing the inner-sphere water ligands and muting the pH-dependent relaxivity effect. This was especially true for the adipate derivative ($n=2$, Scheme 1).

To increase relaxivity and the dynamic range even further for this class of compounds, we sought to make them more avid for serum albumin. Non-covalent protein binding is a well-established technique for increasing the relaxivity of paramagnetic complexes.^[13] Slowing molecular tumbling increases the efficiency of nuclear relaxation by the metal ion. For $q=1$ complexes, the protein-bound relaxivity can be on the order of $60 \text{ mm}^{-1}\text{s}^{-1}$ at 0.5 T and $30 \text{ mm}^{-1}\text{s}^{-1}$ at 1.5 T.^[13a,14] Gianolio et al. showed that a $q=2$ complex can have an albumin-bound relaxivity of $84 \text{ mm}^{-1}\text{s}^{-1}$ at 0.5 T and over $60 \text{ mm}^{-1}\text{s}^{-1}$ at 1.5 T.^[15] On the other hand, albumin-bound $q=0$ complexes tend to have much lower relaxivities. We reported $q=0$ complexes with albumin-bound relaxivities of $5\text{--}6 \text{ mm}^{-1}\text{s}^{-1}$ at 1.5 T.^[14c,16] Thus, in principal, it should be possible to obtain a pH probe the relaxivity of which varies by a factor of ten from low pH to high pH at the common clinical field strength of 1.5 T.

With such a large change in relaxivity (6 to $60 \text{ mm}^{-1}\text{s}^{-1}$) even small changes in pH would be amplified. For instance, by using a pK_a of 6.7 from Lowe et al.,^[4a] one predicts a relaxivity difference of $15 \text{ mm}^{-1}\text{s}^{-1}$ between pH 7.4 (normal) and pH 6.8 (ischemia, tumor); on a percentage basis this would be a 100% change in relaxivity between these two pH values.


Lowe et al. observed a modest twofold increase in relaxivity for their compounds in the presence of serum albumin, but they did not report binding data for the albumin interaction.^[4a] Based on the literature, it is likely that their compounds only exhibit a weak interaction with serum albumin; for example, other hydrophilic chelates with a single aryl group have dissociation constants in the millimolar range resulting in only 10–15 % of the complex being bound to protein under physiological conditions.^[17] We have found that biphenyl groups impart sufficient lipophilicity to enhance albumin binding of gadolinium complexes such that > 90 % of the complex is bound under physiological conditions ($\approx 600 \mu\text{M}$ albumin).^[13a,14c,18]

Based on this reasoning, the target complexes for our study were analogues of those reported by Lowe et al.^[4a] and denoted as **Gd-glu** and **Gd-bbu** (Scheme 2). The synthesis strategy was similar to that reported previously but with some modifications. We first prepared the DO3A esters (**g2**) and (**b2**). Prior work utilized the dimethyl ester of 2-bromoglutarate or 2-bromoadipate. For the glutarate derivative we

used benzyl-*tert*-butyl hydroxypentanedioate (**g1**) and converted it to a mesylate for the alkylation. This intermediate was available from prior studies in our laboratory.^[19]

For the adipate derivative, we prepared (*S*)-dibenzyl-2-hydroxyhexanedioate (**b1**) using a similar procedure as Levy et al.,^[19a] and then converted this to a mesylate for alkylation of cyclen. The benzyl ester provided a convenient UV/Vis handle for monitoring the reaction by HPLC. The best conditions for the tris-alkylation were 5 equiv of the respective mesylate, 1 equiv cyclen at 78 °C for 48 h in acetonitrile with potassium carbonate as a base. The major impurity was the bis-alkylated product. The DO3A esters **g2** and **b2** were purified by preparative HPLC.

The biphenylsulfonamide moiety (**a3**) was prepared through Suzuki coupling. For alkylation of the DO3A derivatives, we converted the hydroxyl group to a mesylate (**a4**). Following deprotection, the ligands (**b4**, **g4**) were chelated with either GdCl_3 or EuCl_3 . The final products were purified by preparative HPLC.



Scheme 2. Synthetic scheme for **Ln-bbu** and **Ln-glu**.

Relaxivity: The relaxivities of **Gd-glu** (Figure 1a and Figure S2b in the Supporting Information) and **Gd-bbu** (Figure 1b and Figure S2d in the Supporting Information) were




Figure 1. Relaxivity versus pH at 37°C and 20 MHz for: a) 0.22 mM **Gd-glu** in the absence (●) and presence of 0.79 mM HSA (▲); b) 0.21 mM **Gd-bbu** in the absence (●) and presence of 0.69 mM HSA (▲). Solid lines indicate fits to determine the pK_a of the sulfonamide moiety.

determined as a function of pH in the range 5 to 8.5 (20 MHz, 60 MHz, 310 K). In the absence of HSA, the pH-dependent relaxivity of these two compounds was similar to that reported by Lowe et al.^[4a] Assuming that the change in relaxivity is due to deprotonation of the sulfonamide nitrogen and concomitant change in q , the pK_a for this deprotonation was determined to be 6.49 ± 0.17 for **Gd-bbu** and 6.58 ± 0.07 for **Gd-glu**.

We also noted that for **Gd-bbu** in the absence of protein, the solution became turbid in the pH range 5.5 to 4.5 and the onset of turbidity depended on the concentration of the compound. In this pH range the observed relaxivity appears to rise as a result of aggregation, but then decrease at pH 4.5, which might be a result of microscopic precipitation.

Relaxivity increased at all pH values when this pH titration was repeated in the presence of excess HSA. However, the relaxivity increase at low pH was much less than expected (42% at 20 MHz, pH 5). Instead of rising to $>60 \text{ mm}^2 \text{ s}^{-1}$ as expected for a protein-bound $q=2$ complex, the relaxivity only approached $14 \text{ mm}^2 \text{ s}^{-1}$. At high pH, the relaxivity was in the range expected for a $q=0$ complex bound to albumin. The relaxivity enhancement at pH 8.5

was 260% at 20 MHz for **Gd-bbu**. Similar behavior was observed for **Gd-glu** for which the relaxivity in the presence of HSA was much lower than expected at pH 5. Relaxivities at 60 MHz (Figure S2a and c in the Supporting Information) were slightly lower than at 20 MHz but the shape of the r_1 versus pH curve was the same as for the 20 MHz data.

This anomalously low relaxivity at low pH could arise from several possibilities. First, the affinity of the compound for HSA could be lower at lower pH, either because of a conformational change of the protein or because the phenol moiety on the compound is protonated at lower pH. This would result in fewer compounds bound at low pH and a smaller observed relaxivity increase. An alternative explanation is that the inner-sphere water molecules are displaced when the complex binds to albumin. This has been seen with other protein-bound Gd(DO3A) derivatives, in which presumably a protein side-chain coordinates the Gd and displaces the water ligands.^[14c,16b,20] Lowe et al. found that the presence of the three pendant carboxylates prevented coordinating anions from displacing the inner-sphere water,^[4a] and we anticipated that these pendant carboxylates would block protein side-chains from binding to the metal ion. A third possibility is that the rate of inner-sphere water exchange is slow when the complex is protein bound. This is not expected given the fast water exchange of $q=2$ Gd(DO3A) derivatives, but there is precedence for such an effect.^[21] Finally, we noted an aggregation/precipitation phenomenon at lower pH values and this aggregation could interfere with protein binding and/or hydration state. We performed additional experiments to address these hypotheses.

pH-Dependent aggregation: We repeated the pH titration for **Gd-bbu** and performed dynamic light scattering (DLS) at each pH value. At about pH 5.5 we began to see the appearance of large aggregates (diameter, $d=700 \text{ nm}$) with high polydispersity. Figure 2a shows the DLS results plotted as relative scattering intensity versus pH (a relative scattering intensity of 1 indicates no aggregation). We then explored the effect of adding HSA to the aggregated **Gd-bbu** at pH 5 (Figure 2b). Even at a low HSA:**Gd-bbu** ratio of 0.25, we see an immediate drop in scattering intensity. The large 700 nm aggregate (Figure 2c–e) disappears with addition of HSA, suggesting that the HSA binding of discrete **Gd-bbu** breaks up the aggregation. After addition of HSA, the DLS analysis is the same as for HSA alone, with a single species of diameter of 8 nm. This drop in scattering intensity and loss of aggregation at low HSA:**Gd-bbu** ratios is also consistent with the ability of HSA to bind several copies of **Gd-bbu**, as will be shown below. The fact that the free energy change for HSA binding is greater than that for **Gd-bbu** self-association suggests that the lower-than-expected relaxivity at pH 5 in HSA solution is not due to some aggregation phenomenon.

We also examined whether increasing the ionic strength would alter aggregation (Figure S3 in the Supporting Information). Here, we titrated up to 30 equiv ammonium acetate (NH_4OAc) at either pH 5 (Figure S3a in the Supporting




Figure 2. a) Relative scattering intensity (RSI) compared to pure water as a function of pH for **Gd-bbu** (0.32 mM) in the absence of HSA. b) Effect of added HSA on relative scattering intensity at pH 5, **Gd-bbu** (0.20 mM). Data in (a) and (b) are mean \pm standard deviation for triplicate experiments; solid line indicates absence of aggregation. c) DLS data for 0.20 mM **Gd-bbu** at pH 4.7; d) DLS data for HSA in HEPES buffer at pH 5; e) DLS data for 1.5:1 HSA/**Gd-bbu** at pH 5. All measurements were performed at 37°C.

Information) or pH 6.2 (Figure S3c in the Supporting Information) and monitored the effect on DLS and relaxivity. At pH 5, NH_4OAc caused a reduction in the scattering intensity but did not eliminate scattering. Ammonium acetate also caused a dramatic reduction in relaxivity, dropping r_1 to $2 \text{ mM}^{-1}\text{s}^{-1}$ at high ammonium acetate ratios. This suggests that aggregation is still present but the aggregate is in a different form. The very low relaxivity suggests $q=0$. Interestingly, when we took this pH 5 solution with 30 equiv ammonium acetate and added HSA, the relaxivity rose from 2 to over $12 \text{ mM}^{-1}\text{s}^{-1}$ when 0.5 equiv HSA per **Gd-bbu** were added (Figure S3c in the Supporting Information). We repeated these experiments at pH 6.2 and there was no evidence of aggregation. At pH 6.2, the addition of 30 equiv NH_4OAc had no effect on relaxivity. This latter result is consistent with the work of Lowe et al. who found that the presence of acetate did not reduce the relaxivity of their complexes.^[4a]

Binding to serum albumin: The non-covalent interaction between **Gd-bbu** or **Gd-glu** and HSA was explored over the pH range 5 to 8.5. Protein complex binding was determined by ultrafiltration across a membrane with a M_w 5000 cutoff under conditions of 0.2 mM Gd complex, 0.69 mM HSA, 37°C (ratio $[\text{HSA}]/[\text{GdL}]_{\text{total}} = 3.2$).

The $[\text{Gd}]$ in the filtrate was determined by ICP-MS and this corresponded to the concentration of the unbound complex. Under these conditions, both **Gd-glu** and **Gd-bbu** were highly bound to HSA with the fraction bound ranging from 98.9 to 99.8%. Thus, for the relaxivity experiments, the observed relaxivity equates to the relaxivity of the protein-bound complex.

Although the fluorophenol moiety on the sulfonamide arm could undergo deprotonation over this pH range, it

does not have a measurable impact on protein binding. The anomalously low relaxivity in HSA solution at pH 5 cannot be attributed to a lack of protein binding at low pH.

We noted from the albumin titration experiments that the protein appeared to bind multiple copies of **Gd-bbu**. We investigated this further by performing a full binding isotherm at pH 5, 37°C, and the results were plotted as $[\text{Gd-bbu}]_{\text{bound}}$ per total $[\text{HSA}]$ versus $[\text{Gd-bbu}]_{\text{unbound}}$. Figure 3




Figure 3. Binding isotherm for **Gd-bbu** (37°C, pH 5, 0.80 mM) to HSA (pH 5, from 0.05 to 1.05 mM in HEPES buffer) from the ultrafiltration experiment. Solid line is the best fit to a stoichiometric binding model.

shows a very strong initial binding event followed by additional binding. From the shape of the curve it is clear that the binding does not saturate at 3 equiv **Gd-bbu** bound. The data were fit to a classical stepwise thermodynamic binding model and the binding constants are listed in Table 1 as dis-

Table 1. Stepwise stoichiometric binding constants, expressed as dissociation constants for **Gd-bbu** binding to HSA at 37°C, pH 5.

K_{d1} [μM]	K_{d2} [μM]	K_{d3} [μM]
0.65 ± 0.29	18.3 ± 8.4	1364 ± 387

sociation constants ($K_d = 1/K_a$). The initial binding constant is in the low micromolar range, two orders of magnitude higher affinity than the albumin-binding contrast agent, MS-325.^[13a] This albumin affinity is similar to that we reported for other gadolinium complexes with biphenyl-based binding protein moieties,^[14c,18a] and is in the same range as drugs like warfarin, naproxen, and ibuprofen.^[22]

To account for the presence of aggregation in the unbound state, we ran the binding assay in the absence of protein. In the absence of protein, 65% of the complex concentration was measured in the filtrate and presumably the remainder was aggregated. We assume that this is constant and we used this value to correct our data. Otherwise we will underestimate the amount of unbound **Gd-bbu** and therefore overestimate the affinity for albumin. It should be noted that this correction only has an impact on the data at

high **Gd-bbu**:HSA ratios at which there is more unbound **Gd-bbu**. Applying the correction has little effect on the first binding event.

Relaxivity and hydration number as a function of serum albumin concentration: In our HSA binding studies at pH 5, it was clear that **Gd-bbu** binds to more than one site on HSA. Our initial relaxivity studies employed an excess of HSA in order to favor protein binding. Together, the relaxivity and binding data indicate that the initial high affinity binding site is a low relaxivity site. We next sought to examine whether subsequent binding sites also displayed this anomalous low relaxivity or if relaxivity would increase as additional sites became occupied.

Figure 4 shows a plot of observed relaxivity versus the number of equivalents of HSA added. These data correspond to the light scattering data shown in Figure 2b. We




Figure 4. a) Relaxivity at 37°C, 0.47 T, pH 5, for **Gd-bbu** (0.42 mM) as a function of added HSA. b) Hydration number q of **Eu-bbu** at pH 5 as a function of added HSA. At $[\text{HSA}]/[\text{Eu-bbu}]=0$; \blacktriangle : measurements made on a visible aggregate; \bullet : measurements made on the supernatant.

know from the light scattering data that when 0.5 equiv HSA are added there is no aggregation in solution and essentially all the **Gd-bbu** is bound to HSA. Addition of more HSA results in a rise in relaxivity, which plateaus at 1 equiv HSA. Figure 4 suggests that all binding sites offer low relaxivity at pH 5. This was confirmed in an additional study in which we measured relaxivity and binding as a function of pH for a 4:1 **Gd-bbu**/HSA solution and calculated the relaxivity due to the bound species (Figure S4 in the Supporting Information). Even at 3 equiv **Gd-bbu** bound to HSA, we

see the same relaxivity as for 1 equiv bound, indicating that there is no site-dependent relaxivity.

We next prepared the Eu^{III} analogue and performed luminescence lifetime studies. The difference in luminescence decay rates when measured in H_2O and D_2O is proportional to the number of inner-sphere water molecule ligands, q .^[23] The nature of the inner-sphere lanthanide coordination environment at pH 5 was examined as a function of HSA concentration. We used a custom-designed multimodal confocal imaging system built by Yaseen et al.^[24] to measure the luminescence lifetime of the Eu^{III} excited state. The microscopic imaging device allowed us to measure Eu^{III} luminescence lifetimes on a pixel-by-pixel basis across the entire field of view ($\sim 600 \mu\text{m}$; Figure S6a, b and c in the Supporting Information). The q values that we report in Figure 4b are averages of these local pixel-wise q values, and the standard deviations reported are those from the averaged q values. Figure 4b shows measured q as a function of HSA added at pH 5. Prior to adding HSA and at the first addition of 0.22 equiv HSA we observed a wide range of q values. However, at the next addition of 0.33 equiv HSA and for subsequent additions (0.5–2.6 equiv) this heterogeneity was eliminated and the q value settled at 0.2 ± 0.1 over this range.

This spatially resolved q mapping was useful for measurements in the absence of HSA when the aggregated **Gd-bbu** is heterogeneous. Figure S4 in the Supporting Information shows microscopic images of the slide prior to HSA addition and indicates that parts of this large aggregate are starting to precipitate. The first two experimental points on the left of Figure 4b ($[\text{HSA}]/[\text{Eu-bbu}]=0$) show two values. The higher value corresponds to $q=1.2 \pm 0.8$, and this was measured in the liquid (supernatant) surrounding the visible aggregate. The lower point, with a value of $q=0.6 \pm 0.8$, corresponds to the average of the solvation state within the aggregate. The large standard deviations reflect the heterogeneous nature of the soluble and insoluble aggregates. After the first addition of HSA, aggregation was still observed, explaining the low precision of the data. After the second addition of HSA, which brought the ratio of $[\text{HSA}]/[\text{Eu-bbu}]$ to 0.33, microscopic observation showed no precipitation, and mean luminescent lifetimes throughout the sample became highly precise with $q=0.2 \pm 0.1$. Additional aliquots of HSA also resulted in precise measurements of q that were unchanged. This behavior of aggregation followed by solubilization with HSA is entirely consistent with the DLS data shown for **Gd-bbu**. The unchanging relaxivity data with $[\text{HSA}]:[\text{Gd-bbu}] > 3$ is consistent with luminescence lifetime data for **Eu-bbu**, when q is low and does not change over this range. The q value estimation is based on an empirical equation that has some uncertainty due to the quenching effects of other X–H oscillators. Thus, a q value of 0.2 likely indicates no inner-sphere water ligands.

To summarize the data so far, we prepared biphenyl analogues of $\text{Ln}(\text{DO3A})$ type complexes previously reported by Lowe et al.^[4a] in order to promote albumin binding and enhance pH-dependent relaxivity. In the absence of albumin, these compounds behaved as expected: low relaxivity at

high pH due to coordination of sulfonamide arm and high relaxivity at lower pH when sulfonamide is protonated and q changes from 0 to 2. The biphenyl compounds show high affinity for serum albumin over the pH range 5–8.5. At pH 8.5, relaxivity increased by 260 % upon albumin binding, but the magnitude of relaxivity was in line with what we expected for a $q=0$ complex bound to albumin. At low pH, the relaxivity of the albumin-bound complex increased but was much, much lower than expected for a putative $q=2$, albumin-bound complex. Luminescence studies on the Eu^{III} analogue revealed that the complex was $q=0$ at pH 5 when bound to albumin, and this explained the low relaxivity.

The lack of inner-sphere water at low pH when protein-bound was surprising. While most $q=2$ $\text{Gd}(\text{DO3A})$ derivatives are well-known to bind coordinating anions resulting in displacement of coordinated water and reduced relaxivity,^[12,20,25] Lowe et al. showed that the presence of the pendant carboxylate groups, and especially the adipate derivative, effectively suppressed anion binding.^[4a] There is also precedence for displacement of inner-sphere water from $\text{Gd}(\text{DO3A})$ derivatives by protein side-chains.^[16b,20] We were aware of these studies and hypothesized that the pendant carboxylate groups would also suppress protein side-chain coordination. In our case, it is not clear why the inner-sphere waters are displaced when the complex binds to albumin. It could be that the high local concentration of glutamate or aspartate carboxylate residues in the binding pocket results in coordination to the Gd^{III} . If side-chain coordination is occurring, one may expect that this might not occur at different binding sites because there might not be a suitable side-chain donor atom in close proximity to the Gd^{III} . However, we found that the relaxivity did not vary for the first three binding sites. An alternate explanation is coordination of one of the pendant carboxylates to the Gd^{III} ion. This would involve an 8-membered chelate ring and would not be expected to be very stable. In aqueous solution, the solvation energy of these pendant carboxylates is very high and coordination to Gd^{III} is not energetically favored. In the HSA binding site, the dielectric constant will be much lower and the pendant carboxylates will be less well-solvated.^[26] These low dielectric conditions can favor coordination of a pendant carboxylate to Gd^{III} .

Regardless of the mechanism, these complexes are $q=0$ when bound to HSA at either high or low pH, yet there is still a pH-dependent relaxivity for the albumin-bound complex. To investigate the nature of this pH dependence, we studied the field-dependent relaxivity of **Gd-bbu** as a function of pH and temperature.

Nuclear magnetic relaxation dispersion (NMRD): Figure 5a shows NMRD profiles of **Gd-bbu** in the absence of HSA at pH 5 and 8.5 at 37 °C. These profiles are consistent with our observations. At pH 5, **Gd-bbu** forms large aggregates and this results in an increase in the rotational correlation time of the $\text{Gd}\rightarrow\text{H}$ vector. It is well established from theory and practice that such an increase in correlation time will result in a maximum in the NMRD profile in the 20–40 MHz




Figure 5. Nuclear magnetic relaxation dispersions (NMRD) of **Gd-bbu**: a) 0.52 mM in the absence of HSA at pH 8.5 and 5, and 37 °C; b) 0.39 mM at pH 8.5 with 1.4 mM HSA at 5 and 37 °C; c) 0.33 mM at pH 5 with 1.3 mM HSA at 5 and 37 °C. Solid lines in (b) and (c) are fits to the data; see text for model and Table 2 for parameters.

range.^[27] At pH 8.5, at which there is no evidence of aggregation, we observe a typical sigmoidal shaped curve consistent with a short correlation time.

In the presence of HSA, there is an increase in relaxivity at both pH values and temperatures (5 and 37 °C) and a peak is observed in the NMRD profile in the 20–30 MHz range. This peak is indicative of a long correlation time. We hypothesize that the increase in relaxivity upon binding is due to the presence of a relatively long-lived water molecule(s) or exchangeable proton(s) in close proximity to the Gd^{III} ion, that is, a long-lived second-sphere water molecule. The NMRD data were modeled to test this hypothesis.

Relaxivity can be factored into contributions arising from different classes of exchangeable protons in the different coordination spheres: inner-sphere, second-sphere, and outer-sphere. Based on the luminescence data, there are no inner-

sphere water ligands when **Gd-bbu** is bound to HSA. This leaves second- and outer-sphere contributions to the observed relaxivity. Relaxation due to outer-sphere water molecules and exchangeable protons (water molecules or NH or OH protons from the protein) that undergo fast exchange ($>10^9 \text{ s}^{-1}$) will result in an NMRD profile that is sigmoidal in shape and lacks the high-field peak. Relaxation due to a nearby long-lived water molecule or exchangeable proton (second-sphere residency time $\tau_m' > 1 \text{ ns}$) will result in this high-field peak in the 20–30 MHz range. We assumed that the relaxivity of the former (fast exchanging protons) could be approximated by the relaxivity of **Gd-bbu** at pH 8.5 in the absence of protein. This is summarized in Equation (1), with which we define a relaxivity due to a long-lived water molecule (or other exchangeable proton(s)), r_1^{LL} :

$$r_1^{\text{LL}} = r_1^{\text{obs}} - r_1^{\text{pH8.5,HSA-}} = \frac{q'/[\text{H}_2\text{O}]}{T_{1m}} = \frac{q'C}{r_{\text{GdH}}^6} \left[\frac{3\tau_c}{1 + \omega_H^2\tau_c^2} \right] \quad (1)$$

$$C = \left(\frac{2}{15} \left(\frac{\mu_0}{4\pi} \right)^2 \gamma_H^2 g_e^2 \mu_B^2 S(S+1) \right) \quad (2)$$

The NMRD of the slow exchanging proton(s) was modeled by using Solomon–Bloembergen–Morgan (SBM) theory.^[28] Since SBM is a high-field theory, we only considered data from 8–400 MHz; at lower fields the assumption that the Zeeman energy is much greater than the static zero field splitting breaks down and use of SBM is not appropriate.^[16a]

At these higher fields, there is only one relevant spectral density term to consider. Furthermore, the lifetime of the long-lived water molecule is still much shorter than its relaxation time, $\tau_m \ll T_{1m}'$, which is apparent from the fact that relaxivity is much higher at 5 °C than at 37 °C (Figure S7 in the Supporting Information, r_1 vs. temperature for ratio 4:1 **Gd-bbu**/HSA). Together this results in a simple analytical expression for r_1^{LL} that depends on the correlation time of the long-lived water, τ_c , and the ratio of the number of long-lived water molecules (q') to the gadolinium–hydrogen distance, q'/r^6 , Equation (1); here C is a constant [Eq. (2)] the symbols have their usual meanings.^[27] The correlation time can have contributions from rotation of the complex ($1/\tau_R$), electronic relaxation ($1/T_{1e}$), and the exchange of the long-lived water ($1/\tau_m'$) [Eq. (3)]. The shortest correlation time will dominate. Electronic relaxation is field-dependent and can be approximated by Equation (4):

$$\frac{1}{\tau_c} = \frac{1}{\tau_R} + \frac{1}{T_{1e}} + \frac{1}{\tau_m'} \quad (3)$$

$$\frac{1}{T_{1e}} = \frac{\Delta^2 [4S(S+1) - 3]}{25} \left[\frac{\tau_v}{1 + \omega_s^2\tau_v^2} + \frac{4\tau_v}{1 + 4\omega_s^2\tau_v^2} \right] \quad (4)$$

We took a global analysis approach to fitting the data. While data at each pH were considered independently, we fit the 37 and 5 °C data together for each pH. Since, electronic relaxation of polyaminocarboxylato Gd^{III} complexes is not very temperature dependent over this range,^[14c,16a,29]

we considered τ_v and Δ^2 to be global parameters. We also assumed that the rotational correlation time of the albumin-bound complex would be much longer than the lifetime of the long-lived second-sphere water molecule, that is, $1/\tau_m' \gg 1/\tau_R$, and thus the relaxivity measurement would not be very sensitive to τ_R . The NMRD data at two temperatures were then simultaneously fit by iteratively varying six parameters: τ_m' (37 °C), τ_m' (5 °C), q'/r^6 (37 °C), q'/r^6 (5 °C), τ_v and Δ^2 ; τ_R was fixed at 40 ns. After this initial analysis, we found that the fitted NMRD data were rather insensitive to the value of τ_R , so long as τ_R was long ($>20 \text{ ns}$). We also found that τ_v and Δ^2 were strongly correlated and could not be independently determined. Ultimately, we were able to reproduce the two NMRD curves (5 and 37 °C) at either pH by varying only five parameters, τ_m' (37 °C), τ_m' (5 °C), q'/r^6 (37 °C), q'/r^6 (5 °C), and Δ^2 (or τ_v), and the results of these fits are given in Table 2. For electronic relaxation, we could identify lower limits on τ_v and Δ^2 and establish a linear relationship between these parameters; at pH 5, $\Delta^2 \geq 5 \times 10^{18} \text{ s}^{-2}$ with $\tau_v = 9.0 \times \Delta^2 - 19.9$ (in ps). At pH 8.5, $\Delta^2 \geq 6 \times 10^{18} \text{ s}^{-2}$ with $\tau_v = 5.3 \times \Delta^2 - 9.4$.

Table 2. Molecular parameters obtained from fit of ^1H NMRD data in Figure 5.

Parameter	pH 5	pH 8.5
τ_R [ns]	$>20^{\text{[a]}}$	$>20^{\text{[a]}}$
τ_m' (37 °C) [ns]	1.8 ± 0.5	1.1 ± 0.2
τ_m' (5 °C) [ns]	2.5 ± 0.6	1.5 ± 0.2
$r_{\text{Gd-H}}$ (37 °C) [Å]	$4.19 \pm 0.14^{\text{[b]}}$	$4.32 \pm 0.11^{\text{[b]}}$
$r_{\text{Gd-H}}$ (5 °C) [Å]	$3.86 \pm 0.05^{\text{[b]}}$	$4.18 \pm 0.07^{\text{[b]}}$

[a] Fixed in fitting at 40 ns; [b] assumes one long-lived water molecule, that is, 2 equiv protons.

The NMRD analysis revealed that the lifetime of the long-lived water molecule is similar at pH 8.5 and 5. The difference in relaxivity arises from a variation in the distance between the Gd^{III} ion and this water molecule, which is shorter at pH 5. This difference in Gd–H distance might be expected. First, at high pH, the sulfonamide group is coordinated to the Gd^{III} and this coordination will change the orientation of the biphenyl HSA binding group with respect to the gadolinium chelate compared to the situation at pH 5, at which the sulfonamide is protonated and not coordinated. If the HSA binding pocket is the same at both pH values, then the Gd chelate will be oriented differently resulting in a different distance to the long-lived water. Changes in protein structure could also give rise to this change in Gd–H distance. For instance, Qiu et al. reported studies on the solvation dynamics and local rigidity in a series of reversible conformations of HSA under different pH conditions.^[30] They observed that HSA undergoes a series of reversible conformational changes from acidic to basic conditions and even a change by a factor of ten of the water exchange rate at the surface. From acidic to neutral pH, structural changes occur in domains II and III, changes in viscosity, solubility, and α -helical content in the protein were observed. As pH in-

creases, HSA shows an increased affinity for some ligands, like warfarin.^[31]

We used the simplest model to reproduce the NMRD curves; no doubt, more complicated models could be used. It is interesting to note that the data could be well-reproduced with a simple isotropic model. Most NMRD data involving macromolecular systems require the Lipari-Szabo modification to account for internal motion.^[32] However, in our case, the correlation time is dominated by the short (≈ 1 ns) lifetime of the long-lived water molecule and the relaxivity data are insensitive to rotational dynamics. The distances reported in Table 2 are based on one long-lived water molecule with two protons, however, the adjustable parameter is q/r^6 . The NMRD data cannot distinguish between a water molecule or a nearby exchangeable proton from the protein.

The **Gd-glu** system showed similar relaxivity data when bound to HSA. Although we did not perform either luminescence studies on the Eu^{III} analogue or NMRD, it is highly likely that the relatively small relaxivity observed at low pH is due to displacement of inner-sphere water molecules as well. Interestingly, the **Gd-glu** system had a U-shaped pH dependence when bound to HSA (Figure 1 a). HSA undergoes the normal-to-base form (N \rightarrow B) conformational transition above pH 8.^[33] It is likely that this results in a change in the internuclear distance between the Gd^{III} ion and the long-lived water. However, the **Gd-bbu** relaxivity is not sensitive to this N \rightarrow B transition.

The majority of water molecules hydrating proteins have residency times on the order of tens of picoseconds, but it is well-established that some water molecules can have longer residency times.^[34] The 1–2 ns lifetime of the long-lived water molecule observed here is in accord with a water molecule hydrogen bonded to the surface of a protein. Interestingly, other albumin-bound $q=0$ complexes show similar behavior.^[14c,16a] The combination of NMRD and $q=0$ complexes could be used to probe the dynamics of protein hydration.

Conclusion

Two new pH-dependent MR contrast agents were synthesized with high affinity for serum albumin. The agents were designed to have no inner-sphere water ligands at high pH (low relaxivity). Pendant carboxylate groups were included to prevent anion binding to the complex at low pH, and it was hoped, to prevent displacement of inner-sphere water ligands by protein side-chains. However, when the complex was bound to HSA at pH 5, the water ligands were displaced and the relaxivity was substantially lower than anticipated. These results suggest that the $[\text{Gd}(\text{DO3A})(\text{H}_2\text{O})_2]$ moiety is not suitable for use in protein targeted contrast agents due to water displacement upon protein binding. Despite being $q=0$ while bound to HSA over the pH range 5–8.5, a pH-dependent relaxivity was still observed. This was due to a long-lived water molecule or other exchangeable

protons in close proximity to the Gd^{III} ion. As the pH was lowered, the distance between this water and the Gd^{III} ion decreased resulting in a pH-dependent relaxivity increase.

Experimental Section

Instrumentation: Ultrafiltration units (UFC3LCC00, regenerated cellulose membrane of 5000 Da nominal molecular weight cutoff) were obtained from Millipore Corp. (Bedford, MA). All gadolinium concentrations were determined by ICP-MS on an Agilent 7500a system. ^1H and ^{13}C NMR spectra were recorded on a Varian 500 NMR system equipped with a 5 mm broadband probe. Longitudinal relaxation times, T_1 , were measured by using the inversion recovery method on Bruker Minispecs mq20 (20 MHz) and mq60 (60 MHz). The $1/T_1$ NMRD profiles were measured on a Stelar Spinmaster fast-field cycling NMR relaxometer (2.35×10^{-4} –0.47 T; ^1H Larmor frequencies: 0.01–20 MHz) equipped with a VTC90 temperature control unit, on Bruker Minispecs (0.71 T [30 MHz], 0.94 T [40 MHz] and 1.41 T [60 MHz]) on a Bruker Avance-200 console connected to 2.35 T (100 MHz) and 4.7 T (200 MHz) cryomagnets, and on a Bruker DRX-400 (9.4 T, 400 MHz). Microwave irradiation was carried out by using a personal chemistry Emrys optimizer microwave synthesizer. Purifications were performed by using two methods. Method A: normal phase chromatography on a Combiflash Companion/TS (Teledyne ISCO, 120 g RediSep R_f silica cartridge) by using A: hexane, B: ethyl acetate, flow-rate 85 mL min^{-1} over 15 min. Method B: preparative HPLC on a Rainin, Dynamax (column: 250 mm Kromasil C18) by using A: 0.1 % TFA in water, B: 0.1 % TFA in MeOH, flow-rate 15 mL min^{-1} over 15 min. HPLC purity analysis (both UV and MS detection) were carried out on an Agilent 1100 system (column: Phenomenex Luna, C18(2) $100 \times 2 \text{ mm}$) with UV detection at 220, 254 and 280 nm by using a gradient of ammonium formate (20 mM, pH 6.8) with 5 % (9:1 ACN/20 mM ammonium formate) to 95 % (9:1 ACN/20 mM ammonium formate), flow-rate 0.8 mL min^{-1} over 15 min.

Luminescence: Measurements were collected by using the confocal portion of a custom-designed multimodal microscope.^[21] Briefly, a continuous-wave diode laser ($\lambda = 532 \text{ nm}$, B&W Tek) provided excitation light that was temporally gated by an electro-optical modulator (ConOptics, Danbury, CT) with extinction ratio of approximately 200 at 532 nm. The excitation beam passed through several conditioning optics, including a beam expander with pinhole spatial filter, polarizer, shutter, dichroic mirror, scan lens, and tube lens and a $20\times$ magnification objective lens (XLumPlan FL, Olympus, NA=0.95). With the use of a customized control software and galvanometric scanners (Cambridge Technology, Inc. Lexington, MA) the excitation beam was guided to selected locations in the approximately $600 \mu\text{m}$ field of view. The emitted luminescence was descanned and collected by using an avalanche photodiode photon counting module (APD, SPCM-AQRH-10, Perkin-Elmer, Waltham, MA) sampled at 50 MHz with a high-speed DIO card (National Instruments, Austin, TX). Data were processed by using custom-written software in C and MATLAB (Mathworks, Natick, MA). Detected luminescent photons were binned into 50 μs long bins, to yield time-dependent phosphorescence decay profiles. With the use of a nonlinear least squares fitting routine, the resulting time-courses were fit with a single-exponential function. A sample's luminescence lifetime is equal to its fitted profile's calculated time constant.

Chemicals: HSA (Fraction V powder 96–99 % albumin, containing fatty acids) was purchased from Sigma Chemical Co. (St. Louis, Mo.). The synthesis of ligands was carried out as shown in Scheme 2. (4-(Benzyloxy)-3-fluorophenyl)boronic acid was purchased from Frontier Scientific, Inc., and (S)-2-aminohexanedioic acid (98 %) was purchased from Alfa Aesar (A Johnson Matthey Company). Other reagents were supplied by Aldrich Chemical Co., Inc., and were used without further purification. Solvents (HPLC grade) were purchased from various commercial suppliers and used as received.

4-Bromo-N-(2-hydroxyethyl)benzenesulfonamide (a2): Chlorotrimethylsilane (1.30 g, 12.0 mmol) was added to a stirred mixture of 2-aminoetha-

nol **a1** (665 mg, 10.89 mmol) and Et₃N (1.29 mg, 13.0 mmol) in CH₂Cl₂ (50 mL) cooled to 0–5 °C in an ice-bath and monitored by TLC (CH₂Cl₂/MeOH/Et₃N 92:8 stained with ninhydrin) for completeness. After 1 h, the mixture was warmed to room temperature while being stirred and was then concentrated, in vacuo. 4-Bromobenzene-1-sulfonyl chloride (3.05 g, 12.0 mmol) was then added and Et₃N (1.31 g, 13.0 mmol) in CH₃CN (50 mL) cooled to 0–5 °C in an ice-bath and monitored by TLC (hexane/ethyl acetate 80:20) for completeness. After 1 h, the mixture was warmed to room temperature while being stirred. After 2 h, the mixture was concentrated, in vacuo, and purified by using normal phase chromatography (method A) to give **a2** (2.02 g, 7.19 mmol, yield 66%). ¹H NMR (CDCl₃, 500 MHz, 303 K): δ = 7.95 (4H), 7.75 (NH), 4.44 (OH), 3.85 (2H), 3.74 ppm (2H); ¹³C NMR (CDCl₃, 125 MHz, 303 K): δ = 139.6, 133.2, 130.7, 127.9, 61.4, 48.4 ppm; LC/MS (ESI⁺): C₈H₁₀BrNO₃S; *m/z* (%): calcd 281.15 [MH⁺]; found: 281.1 (MH⁺).

4'-(Benzyloxy)-3'-fluoro-N-(2-hydroxyethyl)-[1,1'-biphenyl]-4-sulfonamide (a3): Compound **a2** (48.1 mg, 0.17 mmol) and (4-(benzyloxy)-3-fluorophenyl)boronic acid (49.85 mg, 0.202 mmol) were dissolved in ethanol (5 mL) in a microwave vial. Pd(PPh₃)₂Cl₂ (12 mg, 0.017 mmol) and Et₃N (347.5 mg, 3.44 mmol) were added, and the reaction mixture was irradiated in the microwave synthesizer at 100 °C for 30 min. After the reaction was cooled to room temperature, the product was filtered, the filtrate was concentrated, and the crude mixture was purified by using normal phase chromatography (method A) to give **a5** (28.1 mg, 0.07 mmol, yield 42%). ¹H NMR (CDCl₃, 500 MHz, 303 K): δ = 7.75 (4H), 7.45 (NH), 7.40 (2H), 7.35 (2H), 7.22 (3H), 7.18 (1H), 5.21 (2H), 3.57 (OH), 2.98 ppm (4H); LC/MS (ESI⁺): C₂₁H₂₀FNO₄S; *m/z* (%): calcd 402.12 [MH⁺]; found: 402.1 (MH⁺).

(S)-Dibenzyl 2-hydroxyhexanedioate (b1): (S)-2-Aminohexanedioic acid (1.00 g, 6.2 mmol) was dissolved in water (8 mL). Concentrated HCl (0.977 mL, 12.1 mmol) was added. A solution of sodium nitrite (2.48 g, 35.98 mmol) dissolved in water (8 mL) was then added very slowly (3 mL h⁻¹) at 0–5 °C. The solution was stirred, overnight. After acidification (pH 2) the product was extracted with ethyl acetate and dried, in vacuo, to give a mixture of 2-hydroxyhexanedioic acid and 5-carboxy-δ-lactone. LC/MS (ESI⁺): diacid C₆H₁₀O₅; *m/z* (%): calcd 163.06 [MH⁺]; found: 163.1 (MH⁺); lactone C₆H₈O₄; *m/z* (%): calcd 145.05 [MH⁺]; found: 145.1 (MH⁺). Then, a solution of 1N KOH (6.2 g, 6.2 mmol) was added in a single portion to a stirred solution of the mixture dissolved in THF (10 mL) and heated at 40 °C for 2 h. The reaction was then concentrated to a solid, in vacuo (55 °C, <30 Torr) dried under vacuum, overnight, and acid was not purified and used crude in the next step. LC/MS (ESI⁺): C₆H₁₀O₅; *m/z* (%): calcd 163.06 [MH⁺]; found: 163.1 (MH⁺). (S)-2-Hydroxyhexanedioic acid (613 mg, 3.78 mmol) was suspended and stirred in DMF (8 mL) and benzyl bromide (1.29 g, 7.56 mmol) was added at room temperature. After being stirred for 8 h, the mixture was concentrated, in vacuo, and was purified by preparative HPLC (method B, gradient of 5 to 65 % solvent B, monitoring at 220 nm). Fractions containing the product were concentrated to give 230 mg of **b1** (0.67 mmol, yield 11%). ¹H NMR (CDCl₃, 500 MHz, 303 K): δ = 7.3 (10H), 5.2 (2H), 5.1 (2H), 4.2 (1H), 2.4 (4H), 1.8 ppm (4H); ¹³C NMR (CDCl₃, 500 MHz, 303 K): δ = 174 (CO), 173 (CO), 135, 128 (aryl), 77.2, 67, 33.6, 20.3 ppm; LC/MS (ESI⁺): C₂₀H₂₂O₅; *m/z* (%): calcd 343.15 [MH⁺]; found: 343.1 (MH⁺).

(2S,2'S,2''S)-Hexabenzyl 2,2',2''-(1,4,7,10-tetra-azacyclododecane-1,4,7-triyl) tri-hexane-dioate (b2): Methanesulfonyl chloride (184 mg, 1.60 mmol) was added to a stirred mixture of **b1** (500 mg, 1.46 mmol) and Et₃N (177 mg, 1.75 mmol) in CH₂Cl₂ anhydrous (30 mL) cooled to 0–5 °C in an ice-bath and monitored by HPLC for completeness. After the addition was complete, the mixture was warmed to room temperature while being stirred. After 1 h, the mixture was concentrated, in vacuo, and purified by using normal phase chromatography (method A) to give **b5** (580 mg, 1.38 mmol). LC/MS (ESI⁺): C₂₁H₂₄O₅S; *m/z* (%): calcd 421.13 [MH⁺]; found: 421.1 (MH⁺). The mesylate **b5** (840 mg, 2.0 mmol), as a solution in anhydrous CH₃CN (50 mL), was added to a stirred mixture of cyclen (1,4,7,10-tetra-azacyclododecane; 86 mg, 0.5 mmol) and dry potassium carbonate (553 mg, 4.0 mmol) in CH₃CN (50 mL) preheated to 78 °C, and the reaction was monitored by HPLC for completeness. After

48 h, the reaction mixture was cooled to room temperature, filtered with a 200 nm syringe filter to remove potassium salts and concentrated, in vacuo. The mixture was then purified by preparative HPLC (method B, gradient of 5 to 95 % solvent B, monitoring at 220 nm). Fractions containing the product were concentrated to give 201 mg of **b2** (0.18 mmol, 35 % conversion of cyclen). ¹H NMR (CDCl₃, 500 MHz, 303 K): δ = 7.3 (30H), 5.2 (12H), 4.4 (3H), 3.3 ppm (broad); ¹³C NMR (CDCl₃, 125 MHz, 303 K): δ = 167, 164, 135, 128, 66.2, 45.7, 33.3, 30.1, 20.0 ppm; LC/MS (ESI⁺): C₆₈H₈₀N₄O₁₂; *m/z* (%): calcd 1145.59 [MH⁺]; found 1146.4 (MH⁺).

Hexabenzyl 2,2',2''-(10-(2-(4'-(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-4-yl sulfonamido)ethyl)-1,4,7,10-tetra-azacyclododecane-1,4,7-triyl) trihexanedioate (b3): Methanesulfonyl chloride (91.9 mg, 0.80 mmol) was added to a stirred mixture of **a5** (293 mg, 0.73 mmol) and Et₃N (96 mg, 0.95 mmol) in CH₂Cl₂ anhydrous (20 mL). After the addition was complete, the mixture was warmed to room temperature while being stirred. After 1 h, the mixture was concentrated, in vacuo, and purified by using normal phase chromatography (method A) to give **a4** (312 mg, 0.65 mmol). LC/MS (ESI⁺): C₂₂H₂₂FNO₅S₂; *m/z* (%): calcd 480.10 [MH⁺]; found: 480.5 (MH⁺). The mesylate **a4** (128 mg, 0.27 mmol), as a solution in anhydrous CH₃CN (30 mL), was added to a stirred mixture of **b2** (254 mg, 0.22 mmol) and dry potassium carbonate (92 mg, 0.67 mmol) in CH₃CN (50 mL) preheated to 78 °C, and the reaction was monitored by HPLC for completeness. After 12 h, the reaction mixture was cooled to room temperature, filtered with a 200 nm syringe filter to remove potassium salts and concentrated, in vacuo. The mixture was then purified by preparative HPLC (method B, gradient of 5 to 95 % solvent B). Fractions containing the product were concentrated to give 275 mg of **b3** (0.18 mmol, yield 82%). ¹H NMR (CDCl₃, 500 MHz, 303 K): δ = 7.5–7.92 (42H), 5.2–5.4 (12H), 3.21 (3H), 3.45 ppm (3H); ¹³C NMR (CDCl₃, 125 MHz, 303 K): δ = 20.5, 21.9, 25.3, 29.1, 29.7, 36.1, 38.2, 41.4, 66.7, 71.4, 114.4, 115.1, 116.7, 129.2, 135.7, 173.4 ppm; LC/MS (ESI⁺): C₈₉H₉₈FN₅O₁₅S; *m/z* (%): calcd 1528.68 [MH⁺]; found 1528.8 (MH⁺).

2,2',2''-(10-(2-(3'-Fluoro-4'-hydroxy-[1,1'-biphenyl]-4-ylsulfonamido)ethyl)-1,4,7,10-tetra-azacyclododecane-1,4,7-triyl) trihexanedioic acid (b4): Pd (10 %) on carbon (3.00 g) was added to a methanol solution (20 mL) of **b3**. The mixture was subjected to hydrogen bubbling and stirred for 12 h and monitored by HPLC for completeness. The mixture was then filtered through a fine frit, and the filtrate was concentrated, in vacuo. LC/MS (ESI⁺): C₄₀H₅₆FN₅O₁₅S; *m/z* (%): calcd 898.36 [MH⁺]; found 898.4 (MH⁺).

(2S,2'S,2''S)-5-Tribenzyl-1-tri-tert-butyl-2,2',2''-(1,4,7,10-tetra-azacyclododecane-1,4,7-triyl) tripentanedioate (g2): Methanesulfonyl chloride (214 mg, 1.87 mmol) was added to a stirred mixture of **g1** (500 mg, 1.70 mmol) and Et₃N (192 mg, 1.90 mmol) in CH₂Cl₂ anhydrous (30 mL) cooled to 0–5 °C in an ice-bath and monitored by analytical HPLC for completeness. After the addition was complete, the mixture was warmed to room temperature while being stirred. After 1 h, the mixture was concentrated, in vacuo, and purified by using normal phase chromatography (method A) to give the mesylate form of **g1** (525 mg, 1.41 mmol). LC/MS (ESI⁺): C₁₇H₂₄O₅S; *m/z* (%): calcd 373.13 [MH⁺]; found 373.4 (MH⁺). The mesylate (360 mg, 0.964 mmol), as a solution in anhydrous CH₃CN (25 mL), was added under N₂ to a stirred mixture of cyclen (1,4,7,10-tetra-azacyclododecane; 42 mg, 0.24 mmol) and dry potassium carbonate (268 mg, 1.93 mmol) in CH₃CN (20 mL) preheated to 80 °C, and the reaction was monitored by analytical HPLC for completeness. After 48 h, the reaction mixture was cooled to room temperature, filtered with a 200 nm syringe filter to remove potassium salts and concentrated, in vacuo. The mixture was then purified by preparative HPLC (method B). Fractions containing the product were concentrated to give 86.6 mg of **g2** (0.08 mmol, 36 % conversion of cyclen); LC/MS (ESI⁺): C₅₆H₈₀N₄O₁₂; *m/z* (%): calcd 1001.59 [MH⁺]; found 1002.3 (MH⁺).

(2S,2'S,2''S)-2,2',2''-(1,4,7,10-Tetra-azacyclododecane-1,4,7-triyl)tripentanedioic acid (g3): Compound **a4** was prepared following the same condition described for the synthesis of **b3**. Compound **a4** (90.0 mg, 0.19 mmol) as a solution in anhydrous CH₃CN (15 mL) was added under N₂ to a stirred mixture of **g3** (125 mg, 0.13 mmol) and dry potassium carbonate (52 mg, 0.38 mmol) in CH₃CN (15 mL), preheated to 78 °C, and

the reaction was monitored by HPLC for completeness. After 12 h, the reaction mixture was cooled to room temperature, filtered with a 200 nm syringe filter to remove potassium salts and concentrated, in vacuo. The mixture was then purified by preparative HPLC (method B). Fractions containing the product were concentrated to give 152 mg of **g3** (0.11 mmol, 86 %); LC/MS (ESI⁺): C₇₇H₉₈FN₅O₁₅S: *m/z* (%): calcd 1384.69 [MH⁺]; found 1384.7 (MH⁺).

2,2',2''-(10-(2-(3'-Fluoro-4'-hydroxy-[1,1'-biphenyl]-4-ylsulfonamido)ethyl)-1,4,7,10-tetra-azacyclododecane-1,4,7-triyl)tripentanedioic acid (g4): Pd/C (10 %, 3.00 g) was added to a methanol solution (20 mL) of **g3** (115 mg, 0.08 mmol). The mixture was subjected to hydrogen bubbling and stirred for 12 h. HPLC indicated the completion of the reaction. The mixture was then filtered through a fine frit, and the filtrate was concentrated, in vacuo, and co-evaporated with acetonitrile in order to azeotrope out residual water and to remove any remaining methanol. Then a cocktail of tri-isopropylsilane (5 %), anisole (5 %) and TFA (90 %) was added to the product, stirred for 4 h and monitored by analytical HPLC for completeness; LC/MS (ESI⁺): C₃₇H₅₀FN₅O₁₅S: *m/z* (%): calcd 856.31 [MH⁺]; found 856.3 (MH⁺).

Ln-bbu and Ln-glu: Lanthanide complexes were prepared in aqueous solution following the reaction for compound **b4** and **g4**, respectively, with hydrated LnCl₃ at pH 6 (18 h, 50 °C) then raised to pH 9 (30 min). The purification of **Ln-bbu** and **Ln-glu** was carried out through preparative HPLC with neutral ammonium acetate buffer or pure water/acetonitrile eluent. Each purification method gave a satisfactory LC/MS trace of the final compounds **Ln-bbu** and **Ln-glu** with expected masses. LC/MS (ESI⁺): C₃₇H₄₇FGdN₅O₁₅S (**Gd-glu**): *m/z* (%): calcd 1011.21 [MH⁺]; found: 1011.0; C₄₀H₅₃FGdN₅O₁₅S (**Gd-bbu**): *m/z* (%): calcd 1053.26 [MH⁺]; found: 1053.25; C₄₀H₅₃EuFN₅O₁₅S (**Eu-bbu**): *m/z* (%): calcd 1048.26 [MH⁺]; found: 1048.25; see the Supporting Information for purity analyses.

Preparation of 12.0 % (w/v) HSA: Lyophilized HSA was dissolved in HEPES (50 mM) buffer to generate the HSA solution (12.0 %, w/v). A molecular weight of 66 435 Da was used to estimate % (w/v) to a molar concentration. The protein concentration [HSA] was determined by measuring its absorbance at 280 nm for four dilutions. The linear regression on absorbance versus dilution gave a slope of [HSA] × ε, in which ε is the molar absorptivity of HSA (35 700 M⁻¹ cm⁻¹).

Ultrafiltration measurements of binding of Gd-bbu to HSA: Gd-bbu/HSA samples ranging from 0.051 to 1.0 mM HSA in Gd-bbu (0.4 mM) were made by combining appropriate amounts of 12.0 % (w/v) HSA and 0.8 mM Gd-bbu. Aliquots (400 μL) of these samples were placed in 5 kDa ultrafiltration units, incubated at 37 °C for 20 min, and then centrifuged at 3500 g for 7 min. The filtrates from these ultrafiltration units were used to determine the free concentration of Gd-bbu of each of the samples. Duplicate aliquots were processed for each concentration sample of Gd-bbu in 4.5 % (w/v) HSA. Concentrations of Gd-bbu/HSA samples and ultrafiltrates were determined by measuring the Gd concentration using ICP-MS.

Acknowledgements

L.M. acknowledges the Swiss National Science Foundation for a fellowship (PBELP2-130907). Fabrice Yerly is thanked for providing the program VISUALISEUR/OPTIMISEUR, version 2.3.7 (2010) for least-squares fitting of the NMRD data and the pK_a experiment. We thank Zhaoda Zhang for helpful discussions regarding the synthesis. This work was supported by the National Institute of Biomedical Imaging and Bioengineering (award numbers: R01EB009062 and R21EB009738) and the National Institute of Neurological Disorders and Stroke (R01NS057476).

- [1] a) G. Helmlinger, F. Yuan, M. Dellian, R. K. Jain, *Nat. Med.* **1997**, *3*, 177–182; b) P. Swietach, R. D. Vaughan-Jones, A. L. Harris, *Cancer Metastasis Rev.* **2007**, *26*, 299–310.

- [2] F. H. Tomlinson, R. E. Anderson, F. B. Meyer, *Stroke* **1993**, *24*, 2030–2039; discussion 2040.
- [3] a) R. B. Buxton, L. R. Wechsler, N. M. Alpert, R. H. Ackerman, D. R. Elmaleh, J. A. Correia, *J. Cereb. Blood Flow Metab.* **1984**, *4*, 8–16; b) M. L. Garcia-Martin, G. Herigault, C. Remy, R. Farion, P. Ballesteros, J. A. Coles, S. Cerdan, A. Ziegler, *Cancer Res.* **2001**, *61*, 6524–6531; c) R. J. Gillies, N. Raghunand, G. S. Karczmar, Z. M. Bhujwala, *J. Magn. Reson. Imaging* **2002**, *16*, 430–450; d) X. Zhang, Y. Lin, R. J. Gillies, *J. Nucl. Med.* **2010**, *51*, 1167–1170.
- [4] a) M. Lowe, D. Parker, O. Reany, S. Aime, M. Botta, G. Castellano, E. Gianolio, R. Pagliarin, *J. Am. Chem. Soc.* **2001**, *123*, 7601–7609; b) M. Woods, G. E. Kiefer, S. Bott, A. Castillo-Muzquiz, C. Eshelbrenner, L. Michaudet, K. McMillan, S. D. K. Mudigunda, D. Ogrin, G. Tircsó, S. Zhang, P. Zhao, A. D. Sherry, *J. Am. Chem. Soc.* **2004**, *126*, 9248–9256.
- [5] a) F. K. Kálmán, M. Woods, P. Caravan, P. Jurek, M. Spiller, G. Tircsó, R. Kiraly, E. Brücher, A. D. Sherry, *Inorg. Chem.* **2007**, *46*, 5260–5270; b) S. Zhang, K. Wu, A. D. Sherry, *Angew. Chem.* **1999**, *111*, 3382–3384; *Angew. Chem. Int. Ed.* **1999**, *38*, 3192–3194.
- [6] a) S. Aime, M. Botta, S. Geninatti Crich, G. Giovenzana, G. Palmisano, M. Sisti, *Chem. Commun.* **1999**, 1577–1578; b) M. M. Ali, M. Woods, P. Caravan, A. C. L. Opina, M. Spiller, J. C. Fetting, A. D. Sherry, *Chem. Eur. J.* **2008**, *14*, 7250–7258; c) S. Laus, R. Ruloff, E. Toth, A. Merbach, *Chem. Eur. J.* **2003**, *9*, 3555–3566; d) M. Mikawa, N. Miwa, M. Bräutigam, T. Akaike, A. Maruyama, *J. Biomed. Mater. Res.* **2000**, *49*, 390–395.
- [7] a) M. L. Garcia-Martin, G. V. Martinez, N. Raghunand, A. D. Sherry, S. Zhang, R. J. Gillies, *Magn. Reson. Med.* **2006**, *55*, 309–315; b) N. Raghunand, C. Howison, A. D. Sherry, S. Zhang, R. J. Gillies, *Magn. Reson. Med.* **2003**, *49*, 249–257.
- [8] E. Gianolio, R. Napolitano, F. Fedeli, F. Arena, S. Aime, *Chem. Commun.* **2009**, 6044–6046.
- [9] L. Frullano, C. Catana, T. Benner, A. D. Sherry, P. Caravan, *Angew. Chem.* **2010**, *122*, 2432–2434; *Angew. Chem. Int. Ed.* **2010**, *49*, 2382–2384.
- [10] K.-E. Løkling, R. Skurtveit, A. Bjørnerud, S. L. Fossheim, *Magn. Reson. Med.* **2004**, *51*, 688–696.
- [11] K. B. Hartman, S. Laus, R. D. Bolskar, R. Muthupillai, L. Helm, E. Toth, A. E. Merbach, L. J. Wilson, *Nano Lett.* **2008**, *8*, 415–419.
- [12] R. M. Supkowski, W. D. Horrocks, Jr., *Inorg. Chem.* **1999**, *38*, 5616–5619.
- [13] a) P. Caravan, N. J. Cloutier, M. T. Greenfield, S. A. McDermid, S. U. Dunham, J. W. Bulte, J. C. Amedio, Jr., R. J. Looby, R. M. Supkowski, W. D. Horrocks, Jr., T. J. McMurphy, R. B. Lauffer, *J. Am. Chem. Soc.* **2002**, *124*, 3152–3162; b) R. B. Lauffer, *Magn. Reson. Med.* **1991**, *22*, 339.
- [14] a) S. Aime, M. Chiausa, G. Digilio, E. Gianolio, E. Terreno, *J. Biol. Inorg. Chem.* **1999**, *4*, 766–774; b) S. Avedano, L. Tei, A. Lombardi, G. B. Giovenzana, S. Aime, D. Longo, M. Botta, *Chem. Commun.* **2007**, 4726–4728; c) S. Dumas, V. Jacques, W. C. Sun, J. S. Troughton, J. T. Welch, J. M. Chasse, H. Schmitt-Willich, P. Caravan, *Invest. Radiol.* **2010**, *45*, 600–612; d) V. Jacques, S. Dumas, W. C. Sun, J. S. Troughton, M. T. Greenfield, P. Caravan, *Invest. Radiol.* **2010**, *45*, 613–624.
- [15] E. Gianolio, G. B. Giovenzana, D. Longo, I. Longo, I. Menegotto, S. Aime, *Chem. Eur. J.* **2007**, *13*, 5785–5797.
- [16] a) P. Caravan, G. Parigi, J. M. Chasse, N. J. Cloutier, J. J. Ellison, R. B. Lauffer, C. Luchinat, S. A. McDermid, M. Spiller, T. J. McMurphy, *Inorg. Chem.* **2007**, *46*, 6632–6639; b) S. Zech, W.-C. Sun, V. Jacques, P. Caravan, A. V. Astashkin, A. M. Raitsimring, *ChemPhysChem* **2005**, *6*, 2570–2577.
- [17] a) M. H. Ou, C. H. Tu, S. C. Tsai, W. T. Lee, G. C. Liu, Y. M. Wang, *Inorg. Chem.* **2006**, *45*, 244–254; b) L. Vander Elst, F. Maton, S. Laurent, F. Seghi, F. Chapelle, R. N. Muller, *Magn. Reson. Med.* **1997**, *38*, 604–614.
- [18] a) S. Dumas, J. S. Troughton, N. J. Cloutier, J. M. Chasse, T. J. McMurphy, P. Caravan, *Austr. J. Chem.* **2008**, *61*, 682–686; b) Z. Zhang, M. T. Greenfield, M. Spiller, T. J. McMurphy, R. B. Lauffer, P.

- Caravan, *Angew. Chem.* **2005**, *117*, 6924–6927; *Angew. Chem. Int. Ed.* **2005**, *44*, 6766–6769.
- [19] a) S. G. Levy, V. Jacques, K. L. Zhou, S. Kalogeropoulos, K. Schumacher, J. C. Amedio, J. E. Scherer, S. R. Witowski, R. Lombardy, K. Koppetsch, *Org. Process Res. Dev.* **2009**, *13*, 535–542; b) K. Overoye-Chan, S. Koerner, R. J. Looby, A. F. Kolodziej, S. G. Zech, Q. Deng, J. M. Chasse, T. J. McMurry, P. Caravan, *J. Am. Chem. Soc.* **2008**, *130*, 6025–6039; c) E. Spuentrup, K. M. Ruhl, R. M. Botnar, A. J. Wiethoff, A. Buhl, V. Jacques, M. T. Greenfield, G. A. Krombach, R. W. Gunther, M. G. Vangel, P. Caravan, *Circulation* **2009**, *119*, 1768–1775.
- [20] S. Aime, E. Gianolio, E. Terreno, G. B. Giovenzana, R. Pagliarin, M. Sisti, G. Palmisano, M. Botta, M. P. Lowe, D. Parker, *J. Biol. Inorg. Chem.* **2000**, *5*, 488–497.
- [21] S. G. Zech, H. B. Eldredge, M. P. Lowe, P. Caravan, *Inorg. Chem.* **2007**, *46*, 3576–3584.
- [22] a) R. A. O'Reilly, *J. Clin. Invest.* **1967**, *46*, 829–837; b) B. Honore, R. Brodersen, *Mol. Pharmacol.* **1984**, *25*, 137–150.
- [23] a) W. D. Horrocks, Jr., D. R. Sudnick, *J. Am. Chem. Soc.* **1979**, *101*, 334–340; b) A. Beeby, I. M. Clarkson, R. S. Dickens, S. Faulkner, D. Parker, L. Royle, A. S. de Sousa, J. A. G. Williams, M. Woods, *J. Chem. Soc. Perkin Trans. 2* **1999**, 493–504.
- [24] M. A. Yaseen, V. J. Srinivasan, S. Sakadzic, W. Wu, S. Ruvinskaya, S. A. Vinogradov, D. A. Boas, *Opt. Express* **2009**, *17*, 22341–22349.
- [25] E. Terreno, M. Botta, P. Boniforte, C. Bracco, L. Milone, B. Mondino, F. Uggeri, S. Aime, *Chem. Eur. J.* **2005**, *11*, 5531–5537.
- [26] C. N. Schutz, A. Warshel, *Proteins* **2001**, *44*, 400–417.
- [27] a) P. Caravan, *Chem. Soc. Rev.* **2006**, *35*, 512–523; b) P. Caravan, J. J. Ellison, T. J. McMurry, R. B. Lauffer, *Chem. Rev.* **1999**, *99*, 2293–2352.
- [28] a) I. Solomon, *Phys. Rev.* **1955**, *99*, 559–565; b) N. Bloembergen, L. O. Morgan, *J. Chem. Phys.* **1961**, *34*, 842–850.
- [29] D. H. Powell, O. M. Ni Dhubhghaill, D. Pubanz, L. Helm, Y. S. Lebedev, W. Schlaepfer, A. E. Merbach, *J. Am. Chem. Soc.* **1996**, *118*, 9333–9346.
- [30] W. Qiu, L. Zhang, O. Okobiah, Y. Yang, L. Wang, D. Zhong, A. H. Zewail, *J. Phys. Chem. B* **2006**, *110*, 10540–10549.
- [31] a) W. F. van der Giesen, J. Wilting, *Biochem. Pharmacol.* **1983**, *32*, 281–285; b) S. Wanwimolruk, D. J. Birkett, *Biochim. Biophys. Acta* **1982**, *709*, 247–255.
- [32] G. Lipari, A. Szabo, *J. Am. Chem. Soc.* **1982**, *104*, 4546–4559.
- [33] T. J. Peters, *All About Albumin: Biochemistry Genetics, and Medical Applications*, Academic Press, San Diego, **1996**.
- [34] B. Halle, *Philos. Trans. R. Soc. London Ser. B* **2004**, *359*, 1207–1224.

Received: October 24, 2011
Published online: February 10, 2012